We can all read for ourselves.

Here's the paper on the Brave Dreams clinical trial published in JAMA, claiming benefit for over 50% of patients treated with PTA, with no new lesions in 63% of treated patients after 12 months. https://jamanetwork.com/journals/jamaneurology/fullarticle/2664001#editorial-comment-tab

And here is the accompanying editorial in JAMA--claiming absolutely NO benefit, no reduction in lesions. https://jamanetwork.com/journals/jamaneurology/fullarticle/2664000

So, which is it? What is the truth? Why doesn't Ari Green, the editor of JAMA and author of the editorial, give us his disclosures? Since he didn't, I will.
Dr. Green has received personal compensation for activities with Inception Sciences, Mylan Pharma, Medimmune, and Bionure. Dr. Green has received personal compensation for serving on the board of Inception Sciences. Dr. Green holds stock and/or stock options in Inception Sciences. Dr. Green has received research support from Inception Sciences, Biogen, and Novartis. Dr. Green is the founder and main stock holder in Inception Sciences, where he has been developing his MS remyelination drug http://www.neurology.org/content/88/16_Supplement/S50.003 He has been building hype to encourage investors. I write about the less than stellar results from a study of his drug here: http://ccsviinms.blogspot.com/2017/10/an-otc-antihistamine-drug-remyelinates.html